Exact Sciences (EXAS) Competitors $52.94 -0.49 (-0.92%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$52.94 0.00 (0.00%) As of 09/16/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EXAS vs. BIIB, UTHR, INCY, NBIX, BMRN, EXEL, IONS, MDGL, HALO, and RGENShould you be buying Exact Sciences stock or one of its competitors? The main competitors of Exact Sciences include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), and Repligen (RGEN). These companies are all part of the "biotechnology" industry. Exact Sciences vs. Its Competitors Biogen United Therapeutics Incyte Neurocrine Biosciences BioMarin Pharmaceutical Exelixis Ionis Pharmaceuticals Madrigal Pharmaceuticals Halozyme Therapeutics Repligen Biogen (NASDAQ:BIIB) and Exact Sciences (NASDAQ:EXAS) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends. Is BIIB or EXAS more profitable? Biogen has a net margin of 15.31% compared to Exact Sciences' net margin of -34.19%. Biogen's return on equity of 13.85% beat Exact Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Biogen15.31% 13.85% 8.32% Exact Sciences -34.19%-1.75%-0.76% Do analysts rate BIIB or EXAS? Biogen currently has a consensus price target of $181.65, indicating a potential upside of 26.43%. Exact Sciences has a consensus price target of $68.05, indicating a potential upside of 28.54%. Given Exact Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Exact Sciences is more favorable than Biogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 21 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.32Exact Sciences 0 Sell rating(s) 4 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.88 Does the media favor BIIB or EXAS? In the previous week, Exact Sciences had 9 more articles in the media than Biogen. MarketBeat recorded 30 mentions for Exact Sciences and 21 mentions for Biogen. Biogen's average media sentiment score of 1.41 beat Exact Sciences' score of 0.84 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 15 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exact Sciences 10 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in BIIB or EXAS? 87.9% of Biogen shares are held by institutional investors. Comparatively, 88.8% of Exact Sciences shares are held by institutional investors. 0.2% of Biogen shares are held by insiders. Comparatively, 1.2% of Exact Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, BIIB or EXAS? Biogen has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.68B2.18$1.63B$10.4613.74Exact Sciences$2.76B3.63-$1.03B-$5.43-9.75 Which has more risk and volatility, BIIB or EXAS? Biogen has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. SummaryExact Sciences beats Biogen on 9 of the 17 factors compared between the two stocks. Get Exact Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EXAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXAS vs. The Competition Export to ExcelMetricExact SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.12B$3.12B$5.73B$10.31BDividend YieldN/A2.36%5.90%4.63%P/E Ratio-9.7521.1675.8626.51Price / Sales3.63446.35528.72123.58Price / Cash9.4945.4037.1760.46Price / Book4.089.6212.796.29Net Income-$1.03B-$53.28M$3.28B$270.51M7 Day Performance-3.34%1.01%0.81%1.95%1 Month Performance16.10%4.58%4.60%6.33%1 Year Performance-22.14%8.35%70.39%25.62% Exact Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXASExact Sciences4.7697 of 5 stars$52.94-0.9%$68.05+28.5%-23.8%$10.12B$2.76B-9.757,000Positive NewsShort Interest ↓Analyst RevisionBIIBBiogen4.6916 of 5 stars$141.35+0.5%$185.74+31.4%-28.0%$20.62B$9.68B8.797,605Positive NewsUTHRUnited Therapeutics4.7991 of 5 stars$394.62-1.5%$429.62+8.9%+15.4%$18.07B$2.88B15.631,305Positive NewsInsider TradeINCYIncyte4.721 of 5 stars$86.56-0.1%$82.53-4.7%+26.3%$16.92B$4.24B21.552,617Positive NewsShort Interest ↓NBIXNeurocrine Biosciences4.7452 of 5 stars$143.80-0.2%$160.00+11.3%+15.3%$14.29B$2.36B42.631,800Positive NewsBMRNBioMarin Pharmaceutical4.9544 of 5 stars$56.38-2.4%$92.04+63.3%-22.8%$11.09B$2.85B15.663,040Positive NewsShort Interest ↑EXELExelixis4.6269 of 5 stars$37.69-0.5%$44.06+16.9%+42.5%$10.20B$2.17B18.391,147Positive NewsAnalyst DowngradeIONSIonis Pharmaceuticals3.7691 of 5 stars$61.00-0.4%$67.88+11.3%+50.6%$9.76B$705M-33.151,069Insider TradeMDGLMadrigal Pharmaceuticals4.2483 of 5 stars$453.80+4.8%$471.13+3.8%+83.0%$9.61B$180.13M0.0090HALOHalozyme Therapeutics4.5672 of 5 stars$75.85+1.2%$67.11-11.5%+20.6%$8.76B$1.02B15.42390Positive NewsRGENRepligen4.8336 of 5 stars$120.70-3.1%$169.55+40.5%-14.5%$7.01B$634.44M76.421,778Positive NewsAnalyst Revision Related Companies and Tools Related Companies Biogen Alternatives United Therapeutics Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives BioMarin Pharmaceutical Alternatives Exelixis Alternatives Ionis Pharmaceuticals Alternatives Madrigal Pharmaceuticals Alternatives Halozyme Therapeutics Alternatives Repligen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXAS) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
